Primary Biliary Cholangitis - 15 Studies Found Completed : IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) : Primary Biliary Cholangitis : 2025-08-03 : Seladelpar 10 mg one capsule daily for up to 52 weeks COMPLETED : Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions : Primary Biliary Cholangitis : 2025-08-03 : Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) COMPLETED : An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) : Primary Biliary Cholangitis : 2025-08-03 : Seladelpar 10 mg single oral dose COMPLETED : A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. : Primary Biliary Cholangitis : 2025-08-03 : K-808 single or multi dose extended-release tablets COMPLETED : A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury : Primary Biliary Cholangitis : 2025-08-03 : Single oral dose of CS0159 4mg <<< Previous
